Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Over the last year, Viatris has been busy working to resolve FDA concerns at a critical drug manufacturing plant in India ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities.  | In a Worker Adjustment and Retraining Notification Act alert filed this ...

A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation (NBDF) for a ...

The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...

Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...

The committee’s reputation has taken a nosedive, however, following HHS Secretary Robert F. Kennedy Jr.’s decision to purge ...

GenEdit is sailing toward the clinic with a new name and fresh funding.  | GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 ...